Highlights
- 1Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
- 2
- 3Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
Publications
540 publications
Funding
8 grantsView NIH portfolio on RePORTER ↗
Active
4 grants- PIHT9425-24-1-0227Early detection blood test for universal breast cancer screening to improve early diagnosis for women of all social and ethnic backgroundsU.S. Department of Defense · 2024–2027
- Co-IHHSN261201500003IPersonalized in vitro models to advance precision health equityNational Cancer Institute · 2024–2027 · via Leidos Biomedical Research
- MPIAICF 256067-01Lorenzo Foffano American-Italian Cancer Foundation (AICF) for the period 2025-2026American Italian Cancer Foundation · 2026–2026
- PISRA 230372-02A Program for Metastatic Breast Cancer ResearchMETAvivor Research and Support, Inc. · 2023–2026Contract
Completed grants (4)
- PINFCR 227177-01Development of a platform for high throughput drug screening on CTC-derived organoid in breast and colorectal cancerNational Foundation For Cancer Research · 2022–2025
- PITACF 231113-01The association of HER2 expression on circulating tumor cells with the response to cyclin-dependent kinase 4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancerThe Asco Cancer Foundation · 2023–2024
- PISRA 230297-01MARCKS as a potential targeted therapy in IBCInflammatory Breast Cancer International Consortium · 2022–2024Contract
Clinical research
12 studies
Active
1 study- PINCT06380751A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)PHASE3 · AstraZeneca, PLC · OPEN TO ACCRUAL (as of 2025)Advanced Breast Cancer
Completed & closed trials (11)
- PINCT06103864A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)PHASE3 · AstraZeneca, PLC · CLOSED TO ACCRUAL (as of 2026)Breast Cancer
- PINCT05952557CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of DiseasePHASE3 · AstraZeneca, PLC · CLOSED TO ACCRUAL (as of 2026)Breast Cancer, Early Breast Cancer
- PINCT03990896Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialPHASE2 · The General Hospital Corporation (dba Massachusetts General Hospital) · IRB STUDY CLOSURE (as of 2026)Breast Cancer
- PINCT05238922A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid TumorsPHASE1 · Incyte, Inc. · IRB STUDY CLOSURE (as of 2025)Solid Tumors
- PINCT05511844Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid TumorsPHASE1 · Orum Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2025)HER2-positive Breast Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification; HER2 Gene Mutation
- PINCT06112379A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)PHASE3 · AstraZeneca, PLC · CLOSED TO ACCRUAL (as of 2025)Breast Cancer
- PINCT05501886Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor TherapyPHASE3 · Celcuity, Inc. · CLOSED TO ACCRUAL (as of 2025)Breast Cancer
- PINCT05629585A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)PHASE3 · AstraZeneca, PLC · CLOSED TO ACCRUAL (as of 2024)Breast Cancer
- PINCT03606967Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerPHASE2 · National Cancer Institute · IRB STUDY CLOSURE (as of 2024)Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma
- PINCT04964934A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch StudyPHASE3 · AstraZeneca, PLC · CLOSED TO ACCRUAL (as of 2024)ER-Positive HER2-Negative Breast Cancer
- PINCT05198843Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast CancerPHASE1; PHASE2 · National Cancer Institute · IRB STUDY CLOSURE (as of 2024)Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Inflammatory Carcinoma
News mentions
3 mentionsView all WCM news ↗
- Unusual Tumor Cells May Be Overlooked Factors in Advanced Breast CancerMarch 11, 2026
An enigmatic type of circulating tumor cell called a dual-positive cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine.
- Switch to Experimental Drug after Liquid Biopsy Detection of Breast Cancer Recurrence Improves OutcomesJune 2, 2025
A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.
- Weill Cornell Medicine Receives Grant for Blood Test to Diagnose Breast CancerJanuary 3, 2024
Weill Cornell Medicine researchers received a $2.4 million grant from the U.S. Department of Defense Breast Cancer Research Program to validate a new blood test for the early detection of breast cancer.
Media highlights
1 clip
- Etcamah Grabs FDA Approval For Advanced Breast Cancer With ESR1 MutationsHealio · September 8, 2026
Mentoring
1 menteeAll publications with mentees →
External relationships
Leadership Roles
Biotheryx INC · Precision Medicine Action for Cancer (PMAC)
Other
AstraZeneca, PLC · Datar Cancer Genetics · Merck · Nexomic